Results 81 to 90 of about 1,126 (138)

Thrombin generation to evaluate the complex hemostatic balance of hemophilia A plasma containing direct oral anticoagulant and supplemented by factor VIII

Research and Practice in Thrombosis and Haemostasis
Background: The incidence of cardiovascular diseases is increasing in persons with hemophilia A (HA). Therefore, anticoagulant therapy based on direct oral anticoagulants (DOACs) may be needed, despite the bleeding risk.
Sylvain Lamoine, Vincent Jury, Virginie Fourneyron, Jonathan Douxfils, Dorian Teissandier, Laurie Talon, Thomas Sinegre, Aurélien Lebreton   +7 more
doaj   +1 more source

A Unique Comparison of Tooth Extraction Before and After Emicizumab Prophylaxis in a Patient With Haemophilia A and Inhibitors

Case Reports in Dentistry
Haemophilia A is an inherited X-linked bleeding disorder caused by Factor VIII deficiency; approximately 30% of the patients with haemophilia A develop inhibitors against Factor VIII.
Miki Zaizen, Takahiro Yagyuu, Sachiko Yata, Hiroshi Nakamura, Mitsuhiko Imada, Nobuhiro Yamakawa   +5 more
doaj   +1 more source

Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: A simulation study for individuals with severe haemophilia A [PDF]

Introduction: Valoctocogene roxaparvovec, a gene therapy evaluated in the phase 3 GENEr8-1 trial, supports endogenous factor VIII (FVIII) production to prevent bleeding in people with severe haemophilia A.
Newman, Vanessa, Agarwal, Suresh, Miesbach, Wolfgang, Henshaw, Josh, Hermans, Cedric, Peyvandi, Flora, Sidonio, Robert, Osmond, Dane, Pipe, Steven   +8 more
core   +1 more source

Real-World Impact of Emicizumab and Immunosuppression on Acquired Hemophilia A: A Multicenter Us Cohort [PDF]

Acquired hemophilia A (AHA) is an autoimmune bleeding disorder that is caused by factor VIII (FVIII) autoantibodies with high morbidity and mortality due to bleeding and complications from immunosuppression (IST).
von Drygalski, Annette, Al Banaa, Kadhim, Escobar, Miguel A, Ellsworth, Patrick, Malec, Lynn M, Zhou, Jenny Y, Wu, James F, Kruse-Jarres, Rebecca, Chen, Evan C, Kessler, Craig M, Cafuir, Lorraine, Bryan, Cassandra, Poston, Jacqueline N, Parnes, Aric, Walsh, Christopher, Khan, Osman, Janbain, Maissaa   +16 more
core   +1 more source

Predictive parameters for spontaneous joint bleeding during emicizumab prophylaxis [PDF]

Emicizumab is approved for prophylaxis of patients with hemophilia A (HA). Despite its efficacy in reducing bleeding, a few patients on emicizumab still experience hemarthrosis, but no tool is yet available to identify those at higher risk of spontaneous
Palla, Roberta, Gualtierotti, Roberta, Valsecchi, Carla, Scalambrino, Erica, Novembrino, Cristina, Begnozzi, Valentina, Hassan, Shermarke, Clerici, Marigrazia, Peyvandi, Flora, Arcudi, Sara, Boccalandro, Elena Anna   +10 more
core   +1 more source

Emicizumab long-term outcomes and coagulation biomarkers in mild or moderate hemophilia A without inhibitors (HAVEN 6)

Therapeutic Advances in Hematology
Background Emicizumab, a bispecific monoclonal antibody, substitutes for activated factor (F)VIII, facilitating hemostasis in people with hemophilia A (HA).
Cedric Hermans MD, Víctor Jiménez-Yuste MD, PhD, Giuliana Ventriglia PhD, Anna Kiialainen PhD, Laurent Frenzel MD, PhD, Olivier Catalani MSc, Jerzy Windyga MD, Johannes Oldenburg MD, Christophe Schmitt PharmD, Amy D. Shapiro MD, Johnny Mahlangu MD, Michaela Lehle PhD, Steven W. Pipe MD   +12 more
doaj   +1 more source

Emicizumab for preventing intracranial hemorrhage in infants with severe hemophilia A: a cost-effectiveness analysis

Blood Advances
: Intracranial hemorrhage (ICH) and resulting neurologic disability are severe complications for a subset of infants with severe hemophilia A (HA). Although prophylactic factor replacement reduces bleeding risk, it is typically delayed until after age 1 ...
Samira Glaeser-Khan, Satoko Ito, Manraj Sra, Rhys Richmond, Robert D. Bona, Harlan M. Krumholz, Stacy E. Croteau, Adam Cuker, George Goshua   +8 more
doaj   +1 more source

Best-05 | LONG-TERM EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A: REAL-WORLD EXPERIENCE ACROSS ALL AGES

Bleeding, Thrombosis and Vascular Biology
Background and Aims. Emicizumab has provided people with hemophilia A (PwHA) stable bleed protection across inhibitor status and age groups. Nevertheless, a subset of patients continues to experience bleeding despite adequate treatment exposure.
Arianna Colombo
doaj  

Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence

Therapeutics and Clinical Risk Management, 2020
Silvia Linari, Giancarlo Castaman Department of Oncology, Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, ItalyCorrespondence: Giancarlo CastamanDepartment of Oncology, Center for Bleeding Disorders and Coagulation ...
Linari S, Castaman G
doaj  

Challenges in prophylactic therapy with Emicizumab in patients with hemophilia A: Focus on monitoring tests

Romanian Journal of Laboratory Medicine
This study presents a transversal investigation that we performed at Fundeni hospital (Bucharest, Romania) into the therapeutic benefits and efficacy of Emicizumab, a non-factor therapy, in the context of hemophilia A.
Brinza Melen, Uscatescu Valentina, Hemcinschi Mihai, Chiriac Elisabeta, Gherghe Georgiana, Coriu Daniel   +5 more
doaj   +1 more source